Last reviewed · How we verify
Safety and Clinical Effectiveness of Intravitreal Bevacizumab (Lumiere®) in Patients With Wet Age-related Macular Degeneration (Wet AMD)
The purpose of this clinical trial is to evaluate the safety and clinical effectiveness of intravitreal bevacizumab (Lumiere®) in the single-dose form, for the treatment of patients with wet AMD.
Details
| Lead sponsor | Laboratorio Elea Phoenix S.A. |
|---|---|
| Phase | PHASE3 |
| Status | COMPLETED |
| Enrolment | 22 |
| Start date | Tue Feb 07 2017 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Wed May 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Age-Related Macular Degeneration
Interventions
- Bevacizumab (Lumiere®)
Countries
Argentina